Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacob Lalezari
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 1.24
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -77.36
Financials
Revenue
$0.00-100.0%Net Income
$-19.94MEBITDA
$-6.56MFree Cash Flow
$-7.73MEPS (diluted)
$-0.01Shares Outstanding (diluted)
1.38B+872.2%Operating Expenses
$6.58MCash & Debt
$16.36MReturn of Capital
$374.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-42.70M | $-0.03 |
| 2025 | $-5.92M | $3.75M | $0.00 |
| 2024 | $0.00 | $-49.84M | $-0.05 |
| 2023 | $0.00 | $-79.82M | $-0.10 |
| 2022 | $266.0K | $-210.82M | $-0.43 |
| 2021 | $0.00 | $-174.02M | $-0.30 |
| 2020 | $0.00 | $-139.94M | $-0.34 |
| 2019 | $0.00 | $-56.19M | $-0.21 |
| 2018 | $0.00 | $-50.15M | $-0.28 |
| 2017 | $0.00 | $-25.76M | $-0.19 |
| 2016 | $0.00 | $-25.70M | $-0.27 |
| 2015 | $0.00 | $-25.09M | $-0.44 |
| 2014 | $0.00 | $-12.43M | $-0.27 |
| 2013 | $0.00 | $-9.57M | $-0.32 |
Valuation
CYDYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·1d ago·Positive
CytoDyn to Host Investor Webcast VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (“mCRC”) and metastatic triple-negative breast cancer (“mTNBC”), today announced it will host an investor webcast on Octob…
View source ↗ - Newsglobenewswire.com·8d ago·Positive
…ytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), t…
View source ↗ - Newsmarketbeat.com·27d ago·Positive
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer CytoDyn OTCMKTS: CYDY Chief Financial Officer Robert E. Hoffman outlined the company's clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors.
View source ↗ - Newsglobenewswire.com·31d ago·Positive
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E.
View source ↗ - Newsglobenewswire.com·45d ago·Positive
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has…
View source ↗
Earnings
Thu, Jan 14(in 3 months)
Consensus estimate $-0.05 per share
Typical surprise +82.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 14$-0.01 vs $-0.05beat
- Mon, Aug 31$-0.01 vs $-0.05beat
- Wed, Apr 8$-0.00 vs $-0.05beat
- Fri, Jan 9$-0.01 vs $-0.05beat
Estimates and results for CYDY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CYDY officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CYDY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.